Seek immediate emergency medical assistance or call the poisoning helpline.【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 71
Take the missed dose as soon as possible; however, if less than 6 hours have passed since the next dose, skip the missed dose. Never take a double dos···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 73
Take the missed dose as soon as possible; however, if less than 6 hours have passed since the next dose, skip the missed dose. Never take a double dos···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination of encorafenib and binimetinib for the treatment of patients wi···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 71
Binimetinib, developed by Pierre Fabre in France, was approved by the U.S. Food and Drug Administration (FDA) in 2018, providing a new treatment optio···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
Binimetinib is often used in combination with encorafenib. These two drugs target the same signaling pathway at different points and can synergistical···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 71
While binimetinib offers a new treatment option for melanoma patients, its potential adverse reactions still require careful monitoring during use.Sid···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 71
Anagrelide is a platelet-reducing agent, also known as a platelet production inhibitor. Domestically produced Anagrelide capsules were launched in Chi···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
Anagrelide is a selective platelet-producing inhibitor, approved for marketing in the United States in 1997, and subsequently approved in Europe and o···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
Anagrelide is primarily used to treat thrombocytosis, especially essential thrombocytosis, reducing the risk of thrombosis and improving patients'···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
Braftovi is a targeted therapy specifically for BRAF V600E gene mutations. It is often used in combination with other drugs (such as cetuximab and bim···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 73
Encorafenib is an oral small-molecule BRAF kinase inhibitor developed and manufactured by Pierre Fabre in France. It received marketing approval from ···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
Encorafenib is an oral small-molecule BRAF kinase inhibitor developed and manufactured by Pierre Fabre in France. In 2018, encorafenib received market···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 73
Encorafenib exerts its anti-tumor effect by specifically inhibiting the activity of BRAF mutant protein, thereby blocking tumor cell proliferation and···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 73
Since its initial FDA approval in 2018 for the treatment of melanoma, encorafenib has continued to expand its indications, bringing new treatment opti···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 72
Copyright2024@ BIGBEAR All right reserved BIGBEAR



